

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PuraPharm

PURAPHARM CORPORATION LIMITED

培力控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1498)

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The board of directors (the “**Board**”) of PuraPharm Corporation Limited (the “**Company**”) is pleased to announce that Mr. Chow Stanley (周鏡華) (“**Mr. Chow**”) has been appointed as a non-executive director of the Company with effect from 28 August 2018.

The biographical details of Mr. Chow are set out below:

Mr. Chow, aged 54, has over 21 years of experience as a corporate lawyer in Hong Kong and Canada. From May 1995 to October 1996, Mr. Chow served as a senior manager in the Listing Division of The Stock Exchange of Hong Kong Limited. Mr. Chow joined Allen & Overy, an international law firm, as an associate in November 1996 and served as a partner in its Hong Kong office from May 2000 to January 2009. Then, Mr. Chow joined the Hong Kong office of Latham & Watkins, another international law firm, where he was a partner and the local department chair of the corporate department in Hong Kong from March 2009 to February 2014 and a member of its Initiatives Committee from March 2012 to February 2014. Mr. Chow has been an independent non-executive director of HKBN Ltd., a company listed on the Stock Exchange (stock code: 1310), since 6 February 2015.

Mr. Chow graduated from Queen’s University, Canada with a Bachelor of Commerce (Honours) Degree in May 1986 and obtained a Juris Doctor with Honour Standing from the University of Toronto, Canada in June 1989. Mr. Chow was admitted as a barrister and solicitor in Ontario, Canada in 1991, and in British Columbia, Canada in 1994. He was also admitted as a solicitor in England and Wales in 1994 and in Hong Kong in 1995.

Mr. Chow was a director of Headline Investments Limited, a private company incorporated in Hong Kong engaging in property investment prior to the sale of the relevant property and the subsequent cessation of its business and dissolution of the company by deregistration on 30 June 2011 pursuant to section 291AA of the predecessor Companies Ordinance (Chapter

32 of the laws of Hong Kong). Mr. Chow confirmed that the company was solvent at the time of its deregistration and such deregistration had not resulted in any liability or obligation against him.

The Company has entered into a letter of appointment with Mr. Chow in relation to his appointment as a non-executive director of the Company. He has been appointed for a term of three years, with effect from 28 August 2018. Mr. Chow will hold the office until the forthcoming annual general meeting of the Company and shall then be eligible for re-election in accordance with the articles of association of the Company. He is entitled to a director's fee of HK\$100,000 per quarter, which has been recommended by the remuneration committee of the Board and approved by the Board having considered his responsibilities and job duties, the Company's remuneration policy and the prevailing market conditions.

Save as disclosed above and as far as the directors of the Company are aware, Mr. Chow does not (i) hold any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong); (ii) have any relationship with any other Directors, senior management or substantial or controlling shareholders of the Company; (iii) hold any other position in the Group; and (iv) hold any other directorships in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years.

Save as disclosed above and so far as the directors of the Company are aware, there is no other matter relating to the appointment of Mr. Chow that need to be brought to the attention of the shareholders of the Company and there is no further information to be disclosed pursuant to the requirements of Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Company would like to welcome Mr. Chow in joining the Board.

By order of the Board
PuraPharm Corporation Limited
Chan Yu Ling, Abraham
Chairman

Hong Kong, 27 August 2018

As at the date of this announcement, the executive directors of the Company are Mr. Chan Yu Ling, Abraham, Dr. Tsoi Kam Biu, Alvin, Mr. Chan Kin Man, Eddie, and Ms. Man Yee Wai, Viola; and the independent non-executive directors of the Company are Dr. Chan Kin Keung, Eugene, Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.